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AbstrAct
Introduction A new prognostic model has been developed 
and externally validated, the aim of which is to assist in 
the management of the blunt chest wall trauma patient in 
the emergency department (ED). A definitive randomised 
controlled trial (impact trial) is required to assess the 
clinical and cost effectiveness of the new model before it 
can be accepted in clinical practice. The purpose of this 
trial is to assess the feasibility and acceptability of such a 
definitive trial and inform its design.
Methods/analysis This feasibility trial is designed to test 
the methods of a multicentre, cluster-randomised (stepped- 
wedge) trial, with a substantial qualitative component. Four 
EDs in England and Wales will collect data for all blunt 
chest wall trauma patients over a 5-month period; in the 
initial period acting as the controls (normal care), and in 
the second period acting as the interventions (in which 
the new model will be used). Baseline measurements 
including completion of the SF-12v2 will be obtained on 
initial assessment in the ED. Patient outcome data will 
then be collected for any subsequent hospitalisations. 
Data collection will conclude with a 6-week follow-up 
completion of two surveys (SF-12v2 and Client Services 
Receipt Inventory). Analysis of outcomes will focus on 
feasibility, acceptability and trial processes and will include 
recruitment and retention rates, attendance at clinician 
training rates and use of model in the ED. Qualitative 
feedback will be obtained through clinician interviews and a 
research nurse focus group. An evaluation of the feasibility 
of health economics outcomes data will be completed.
Ethics and dissemination Wales Research Ethics 
Committee 6 granted approval for the trial in September 
2016. Patient recruitment will commence in February 
2017. Planned dissemination is through publication in a 
peer-reviewed Emergency Medicine Journal, presentation 
at appropriate conferences and to stakeholders at 
professional meetings.
trial registration number ISRCTN95571506; Pre-results.
IntroductIon
Blunt chest wall trauma accounts for >15% 
of all trauma admissions to emergency 
departments (ED) worldwide, with reported 
mortality ranging between 4% and 60%.1–3 
The difficulties in the management of the 
blunt chest wall trauma patient in the ED 
are becoming increasingly well recognised 
in the literature.4 5 The blunt chest wall 
trauma patient commonly presents to the 
ED with no respiratory difficulties, but can 
develop complications up to approximately 
72 hours after initial presentation.1–4 Clinical 
symptoms are not considered by most clini-
cians to be an accurate predictor of outcome 
following non-life-threatening blunt chest 
wall trauma.1–7 Decisions regarding the appro-
priate level of care required by the patient 
following discharge from the ED are there-
fore difficult, which is further compounded 
by the lack of current national guidelines. 
An improvement in the ability to identify the 
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strengths and limitations of this study
 ► The main strength of the trial design is that it will test 
all of the methodological components of the future 
definitive trial, including the trial infrastructure, 
randomisation process, data management system, 
both qualitative and quantitative analysis, follow-up 
procedures and a health economic analysis.
 ► The health economic analysis will ensure accurate 
future funding applications for the full definitive trial.
 ► The qualitative analysis will inform the researchers’ 
understanding of the use of the risk score by 
clinicians in daily clinical practice.
 ► The cluster-randomised trial design that needed 
to be tested in this feasibility trial is limited by the 
small number of clusters (emergency departments 
participating). In the future definitive trial, more 
clusters will be possible due to the greater number 
of participating sites.
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Figure 1 Schematic representation of the trial’s timelines. PI, principal investigator.
high-risk blunt chest wall trauma patient on initial assess-
ment in the ED would potentially lead to a reduction in 
these poor outcomes.8 9
A new prognostic model to assist in the management 
of blunt chest wall trauma patients in the ED has been 
developed and externally validated in a large multicentre 
study.1 5–7 The model comprises five risk factors: age, 
number of rib fractures, pre-existing chronic lung disease, 
use of preinjury anticoagulants and oxygen saturation on 
initial assessment in the ED. The patient is scored on each 
risk factor and the total score is used to guide the clinician 
in the ED as to whether the patient should be admitted 
to the ward, critical care unit or can be safely discharged 
home (see online supplementary material 1). Guidelines 
recommend however that prognostic models should not 
be used in clinical practice until an impact study has been 
completed, in which the clinical application of the model 
has been tested.10 11 Prior to undertaking a large defini-
tive randomised controlled trial of the clinical and cost 
effectiveness of the prognostic model, a smaller-scale trial 
is required to address the issues of feasibility and accept-
ability.
trial aims
The aim of this trial (protocol version 5, 6 January 2017) 
is to establish the feasibility and acceptability of the 
final definitive impact trial, which will ultimately deter-
mine whether the prognostic model can be used safely 
and effectively in clinical practice in the UK. The trial 
objectives are to (1) evaluate the infrastructure neces-
sary to perform a future definitive trial, including the 
Trial Management Group, Trial Steering/Data Manage-
ment Committee; (2) test the feasibility of the proposed 
stepped-wedge, cluster-randomised design; (3) evaluate 
and qualitatively explore the compliance of the clini-
cians in using the prognostic model (and reasons for 
non-compliance); (4) assess the appropriateness of the 
training manual and consistency of training provided by 
each principal investigator (PI); (5) quantify the number 
of patients required for a full definitive trial through 
the estimation of the magnitude of effect and necessary 
parameters, including the margin of error acceptable to 
achieve the proposed outcomes; (6) assess the processes 
of patient recruitment, consent and reasons for non-par-
ticipation; (7) assess the quantity and potential patterns 
of missing data; (8) test the feasibility of collecting the 
proposed outcome measures for a full trial, including 
optimal time points, using the electronic case report form 
on the REDCap data collection system; and (9) decide 
whether a fully powered, multicentre randomised trial is 
indicated by formal assessment of feasibility trial findings 
against pre-set progression criteria.
MEthods And AnAlysIs
Trial design and randomisation
This feasibility trial is designed to test the methods of a 
multicentre, prospective, cluster-randomised (stepped-
wedge) trial,12 with a substantial qualitative component. 
Figure 1 outlines the trial procedure. There will be four 
hospitals participating in the trial, which will be run using 
a stepped-wedge design. In accordance with Medical 
Research Council guidance,13 the unit randomisation will 
be the EDs, rather than patients, since the intervention 
will be used by ED clinicians, with the aim of studying 
effects on patient outcomes. All participating EDs will 
begin as control sites, at the same time, testing conven-
tional management without the model, for a period of 
1 month (control arm). Every month, following the initial 
month’s data collection period as controls, one hospital 
will be randomly assigned to become an intervention arm 
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(in which all clinicians in the ED will be using the risk 
model) sequentially, until all hospitals are acting as inter-
ventions.
The randomisation process applies to the hospitals 
(known as clusters) participating in the trial, rather 
than at a patient level. The order in which hospitals 
EDs convert to intervention status is based on a purely 
random process (involving only computer-generated 
random numbers, but no information on the individual 
hospitals or EDs) and can be regarded as equivalent to 
the drawing of names at random. As there are four hospi-
tals participating in the trial, all patient recruitment will 
be completed over a 5-month period. This trial design will 
test the feasibility of the classic stepped-wedge design to 
be used in the future definitive trial.
During the control period, the doctors in each ED 
will receive training on the model from the PI in each 
ED. Each PI will be instructed at the start of the trial on 
how to train the clinicians and a training manual will be 
designed and provided.
Population
Patients will be included in the trial if they present to the 
ED with isolated blunt chest wall trauma, are aged ≥18 
and are capable of giving consent to participation. Poten-
tial patients will be excluded if they are under the age of 
18, lack capacity to give informed consent, present with 
any immediately life-threatening injuries or any concur-
rent injury that will determine the patient’s management 
(rather than the chest trauma). Patients will be withdrawn 
from the trial if they lose capacity (including death) to 
complete the surveys and if they request to be withdrawn. 
These data will be recorded as part of the assessment of 
the trial’s success criteria in order to inform the design of 
the future definitive trial. A list of all patients who decline 
to participate will also be completed in order that the trial 
team can assess the recruitment rates at the end of the 
study.
setting and recruitment
This multicentre feasibility trial will be run in the EDs 
of the Royal Gwent Hospital in Newport, Musgrove 
Park Hospital in Taunton, Salford Royal Hospital and 
Manchester Royal Infirmary (all large teaching hospitals 
located in the UK). The clinicians or research nurses in 
the ED will screen, recruit and consent eligible patients 
to the trial.
sample size
A 5-month recruitment period has been proposed. In 
2015, >1200 blunt chest wall trauma patients presented 
to the ED of the hospital of the trial research team, 
with >100 of these admitted. If the four participating 
hospitals recruit for 5 months each, between 30 and 80 
patients per site should be recruited, allowing for loss to 
follow-up, low response rates with follow-up surveys and 
difficulties with recruiting at weekends if research nurses 
only work Monday to Friday. This sample size is the 
minimum number of participants considered necessary 
to test the processes of data collection, based on existing 
recommendations with respect to the number of patients 
required to yield meaningful estimates of parameters of 
interest.14
The analysis will lead to an estimation of the sample size 
for the definitive trial needed to yield 80% power when 
using a significance level of 5%, by establishing non-infe-
riority between use of the prognostic tool and standard 
care, as revealed by the feasibility study.
The analysis will include descriptive data (means and 
SD) on all outcomes collected, including levels of missing 
data, leading to the calculation of clinically important 
differences. The conventional sample size calculations 
for the future definitive trial will be developed using this 
analysis and the consensus among the Trial Management 
Group and Trial Steering Committee of the minimal 
clinically important difference in these measures. If the 
recruitment and retention plan is shown to be optimistic 
in this feasibility trial, then this is an important finding 
which will inform the sample size calculation for the 
future main definitive trial.
Interventions
The intervention being investigated in this study is the 
use of the prognostic model to guide the clinicians' 
clinical decision-making. The model will be used by the 
clinician during the initial patient assessment and will 
provide a suggestion of the appropriate management 
in terms of whether the patient can be safely discharged 
home or whether they need admission to either a ward or 
critical care. There will be no other differences in patient 
care. Figure 2 describes the patients’ journey through the 
trial. All patients will be required to complete one survey 
(SF-12v2),15 on initial presentation to the ED and two 
more surveys at 6 weeks post injury (SF-12v2 and a Client 
Services Receipt Inventory). A sample of the clinicians 
using the model will be asked to attend a short interview 
in which they will be asked to discuss the model in relation 
to clinical practice. The research nurses will be required 
to attend a focus group in which there will be a discussion 
about the trial’s methodology including specifically issues 
around data collection.
Strategies to improve adherence to interventions
Full training (including a training manual) on the 
use of the model and the trial design will be provided 
for each hospital’s PI, who will then be responsible for 
training the doctors working in their ED. Feedback from 
a sample of the clinicians regarding the model will be 
provided through a short interview, at a convenient time 
and location. All documentation will be available in the 
Welsh language where applicable, working in conjunc-
tion with the Language Awareness Infrastructure Support 
Service. Patients will be offered the chance to be entered 
into a prize draw if they return their surveys at 6 weeks 
post injury.
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Figure 2 Summary of the patients’ journey through trial. ED, 
emergency department.
outcome measures
Primary outcome measure
Patient recruitment rate will be recorded as the number 
of eligible patients who consent to trial participation at 
the end of the 5-month data collection period, at each 
site.
Secondary outcome measures
1. ‘Clinician recruitment rate’ will be recorded as the 
number of eligible clinicians working within the 
participating ED who agree to take part in the study 
by the end of the 5-month data collection period, at 
each site.
2. ‘Response rate of follow-up data’ (quality-of-life 
surveys) will be recorded as the number of patients 
returning postal surveys at the end of the 5-month 
data collection period, at each site.
3. ‘Clinicians Training Attendance rate’ will be recorded 
as the number of clinicians who receive formal 
training in the use of the model, prior to the second 
data collection period (intervention arm), at each 
site.
4. ‘Compliance with use of model rate’ will be recorded 
as the number of times the clinician used the risk 
model for an eligible patient, at the end of the second 
data collection period (intervention arm).
5. ‘Overall mean quality of life’ as reported using the 
SF-12v2 survey for patients, at the end of the control 
and intervention data collection periods (compared 
with baseline taken on initial assessment in the ED), 
at each participating site.
6. ‘Resource usage by patients as a result of the 
intervention’ as reported on the Client Services 
Receipt Inventory at 6-week follow-up.
Data collection
Data collection to be completed by the on-site research 
nurse and will include (1) SF-12v2 survey and prognostic 
model (if used) completed in the ED; (2) mechanism 
of injury, a measure of pre-admission frailty, admission 
status, hospital and intensive care unit (ICU) length of 
stay, occurrence of complications (mortality or pulmo-
nary morbidity) and readmission to hospital will be 
obtained from medical records prospectively, during the 
patient's hospitalisation; and (3) at 6 weeks post injury, 
the second quality-of-life questionnaire (SF-12) and 
Client Services Receipt Inventory will be sent out to the 
patient for completion.
Data collection to be completed by the qualitative 
researcher will include (1) attendance at the PI-led 
training sessions at two sites in order to assess consis-
tency of training provided between sites and the 
appropriateness of the training manual; (2) clinicians 
will be asked to complete an online feedback survey 
after the training session to collect their views about the 
training, for example; travel and time costs incurred, 
completeness, appropriateness and if they have any 
suggestions about possible improvements; (3) a total of 
eight doctors (two from each site) who are using the 
model will be interviewed at the end of the study period 
to understand how the tool was used, ease and time of 
use, as well as problems with its use. If it arises, the study 
team will need to also understand a situation in which 
the model could have been used, but was not used, and 
why that might have occurred. Doctors at participating 
sites who have not used the model (if any) will be invited 
to participate in interviews to explore their reasons; 
and (4) a focus group will be facilitated by the qualita-
tive researcher in which the research nurses responsible 
for data collection will discuss the trial process in depth.
An evaluation of the feasibility of health economics 
outcomes data will be completed as part of the trial. As 
this is a feasibility trial, the focus will be on establishing 
the most appropriate framework for a future health 
economic analysis in the full definitive trial. The feasi-
bility of collecting data on outcome and resource use 
will be assessed. A provisional assessment of the cost 
categories associated with the intervention (eg, staff 
time associated with training and use of the model) 
will be completed through discussion with the qualita-
tive researcher completing the telephone interviews. 
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box 1 trial feasibility criteria
Sample size and participants
1.  ≥95% of clinicians working within the participating 
emergency department agree to take part in the study.
2. ≥80% of eligible patients consent to data collection and follow-up.
3. Follow-up data for primary outcomes can be collected for ≥80% of 
patients.
Interventions
1. All clinicians involved in the trial receive formal training in the use 
of the model.
2. 90% compliance with use of the model during intervention period.
Outcomes
1.  Mean quality of life reported in the intervention arm is not less 
than 80% of that reported in the control arm.
2. Outcome measures reported in the intervention period are equal to, 
or better than, those reported during the conventional management 
period.
To capture resource usage by patients as a result of the 
intervention, from a National Health Service/Personal 
Social Service perspective, an adapted resource usage 
questionnaire will be used. The use of the SF-12v2 will 
be considered as a measure to derive utilities using the 
SF-6D. Data will be assessed to examine the complete-
ness of data captured, such as response rate and 
potential missing items.
data management
Research Electronic Data Capture (REDCap) will be used 
for data capture and for completion of the electronic case 
report forms, hosted at Swansea University.16 REDCap 
is a secure, web-based application designed to support 
data capture for research studies, providing (1) an intui-
tive interface for validated data entry, (2) audit trails for 
tracking data manipulation and export procedures, (3) 
automated export procedures for seamless data down-
loads to common statistical packages and (4) procedures 
for importing data from external sources. The use of the 
REDCap system will be discussed in the focus group with 
the research nurses who will be completing the electronic 
case report forms. Feedback will be used to adapt the 
system to improve the setup, prior to the commencement 
of the full definitive trial.
statistical methods
Quantitative data analysis
Criteria of study success: In order to evaluate the success 
of the feasibility trial, with the view to continue to a full 
definitive impact trial, the Data Monitoring Committee 
will assess the final results using the ACCEPT model, 
developed by Charlesworth et al).17 The predetermined 
success criteria are highlighted in box 1.
Qualitative data analysis
Focus groups and interviews will be audio recorded and 
sent to a professional transcription service for verbatim 
transcription. The qualitative researcher will oversee 
this process and on receipt of transcripts will check 
them for accuracy against the original recording and 
undertake anonymisation in accordance with best prac-
tice standards. The cleaned and anonymised transcripts 
will be uploaded into NVIVO 10—a qualitative data 
analysis program.18 The qualitative researcher will code 
the transcripts thematically using a code book which 
developed initially from the background literature and 
feedback on the training as well as issues which will 
emerge through the process of constant comparison 
which underpins qualitative data analysis. A subsample 
of coded transcripts will be checked by a second quali-
tative researcher (by reciprocal arrangement within the 
wider team at the trials unit) using the coder compar-
ison query tool.
trial monitoring and managemen
An independent, joint Trial Steering/Data Monitoring 
Committee will be formed that has no link to the 
sponsor and has no competing interests. The role of 
the committee will be to monitor adverse and serious 
adverse events, stopping criteria and trial endpoint 
success criteria analysis. Stopping criteria will include 
(1) a 5% increase in each of the hospitals, in the 
number of patients with an unplanned representation 
to the ED due to development of complications, leading 
to I admission and unexpected death (following direct 
discharge from the ED on initial presentation), in the 
intervention period compared with the control period; 
and (2) a 5% increase in each of the hospitals, in the 
number of patients identified as having a delayed 
admission to ICU leading to unexpected death, in the 
intervention period compared with the control period. 
The committee will also be responsible for the overall 
supervision of the trial to ensure the trial is completed 
according to rigorous sta
There will be no direct change to patient care; however, 
once the model has been introduced to each ED, the 
clinicians will be required to use the prognostic model 
to guide their management decisions for the patient. 
The model will only be used as a guide to management; 
however, if the clinician believes the suggestion of the risk 
score places the patient at risk, they can over-ride the prog-
nostic model. This would be documented and reviewed by 
the trial team. Although there are a number of expected 
adverse events for blunt chest wall trauma patients, the 
PI may take appropriate urgent safety measures in order 
to protect research participants against any immediate 
hazard to their health or safety, without prior authorisa-
tion from a regulatory body. Any serious adverse event 
and urgent safety measures will be reported to the CI 
immediately with details of the measure and a plan for 
further action. The chief investigator (CI) or sponsor 
will notify the main Research Ethics Committee and Trial 
Steering Committee. Serious adverse events will include 
(1) death or ICU admission in patients who have been 
discharged home as suggested by the risk score and (2) 
any trial patient complaint.
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EthIcs And dIssEMInAtIon
Ethical issues
This trial has received ethics approval by the Wales 
Research Ethics Committee 6 (ref: 16/WA/0290). Any 
arising important protocol modifications (such as changes 
to eligibility criteria, outcomes, analyses) will be commu-
nicated to the relevant parties (investigators, Research 
Ethics Committee / International Review Board, trial 
participants, trial registries, journals, regulators) in a 
timely manner. Compliance with this will be monitored 
by the trial sponsor (ABMU Health Board R&D Depart-
ment). Informed consent will be obtained by the clinicians 
or research nurses who will all have received ‘protocol 
and informed consent specific training’ in alignment with 
the principles of Good Clinical Practice and who have 
signed the trial delegation log. Consent will be sought, 
following a full introduction to the study and once the 
patient has had time to discuss the Patient Information 
Sheet with a family member/carer (as appropriate). A 
study withdrawal letter will also be attached to the Patient 
Information Sheet in case the patient wishes to withdraw 
consent in the first week following recruitment.
The trial’s CI will take responsibility to ensure that 
patient anonymity is protected and maintained. Infor-
mation with regards to study patients will be kept 
confidential and managed in accordance with the Data 
Protection Act, NHS Caldicott Guardian, The Research 
Governance Framework for Health and Social Care and 
Research Ethics Committee Approval. All patients will 
be allocated a study number once informed consent is 
obtained. Personal data will only be identifiable by this 
study number during data collection. All patient identi-
fiable data will be removed and data anonymised once 
data collection using the survey is complete. The CI will 
act as the custodian of the data and the records will be 
kept securely for a further 5 years in the Health Board 
archive facility. The Caldicott Guidelines will be adhered 
to throughout the study.
dissemination policy
Dissemination of the outputs from this trial is proposed 
through publication in an appropriate Emergency Medi-
cine Journal and by presentation at relevant international 
conferences. The aim of this feasibility trial is not to 
report definitive results regarding clinical and cost effec-
tiveness; however, any important outputs produced in the 
trial related to the prognostic model will be published 
in appropriate medical journals as follow-on articles 
from our previous published work in this area. We will 
disseminate our findings to stakeholders via professional 
meetings. The Trauma and Audit Research Network 
(TARN) newsletter will be used to disseminate the results 
to the Trauma leads in each ED participating in TARN in 
the UK.
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